a novel anti-cd37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of...
TRANSCRIPT
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell
malignancies
by Jutta Deckert, Peter U. Park, Sharon Chicklas, Yong Yi, Min Li, Katharine C. Lai, Michele F. Mayo, Christina N. Carrigan, Hans K. Erickson, Jan Pinkas, Robert J.
Lutz, Thomas Chittenden, and John M. Lambert
BloodVolume 122(20):3500-3510
November 14, 2013
©2013 by American Society of Hematology
Examples of CD37 staining on human lymphoma samples.
Jutta Deckert et al. Blood 2013;122:3500-3510
©2013 by American Society of Hematology
In vitro activity of K7153A antibody on lymphoma cell lines.
Jutta Deckert et al. Blood 2013;122:3500-3510
©2013 by American Society of Hematology
IMGN529 structure and in vitro activity.
Jutta Deckert et al. Blood 2013;122:3500-3510
©2013 by American Society of Hematology
IMGN529 has specific cytotoxicity against CD37+ lymphoma cell lines.
Jutta Deckert et al. Blood 2013;122:3500-3510
©2013 by American Society of Hematology
IMGN529 conjugate induces G2/M cell cycle arrest.
Jutta Deckert et al. Blood 2013;122:3500-3510
©2013 by American Society of Hematology
In vivo efficacy of IMGN529 in tumor xenograft models.
Jutta Deckert et al. Blood 2013;122:3500-3510
©2013 by American Society of Hematology
IMGN529 specifically depletes normal and malignant human B cells.
Jutta Deckert et al. Blood 2013;122:3500-3510
©2013 by American Society of Hematology